DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled “Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study,” which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth’s digital health platform. The study focused on demonstrating the effect of digital engagement on improving monthly average blood glucose levels during a patient’s first year of managing their diabetes on the platform. The study noted that highly engaged users who maintained consistent digital engagement with the platform demonstrated statistically significant improvement during the initial period relative to engaged users, 13% vs. 9% respectively. The study also noted a 43% decrease in monthly average glucose levels in the month following increased digital engagement from the month prior, during the initial six-month period. “A key goal at DarioHealth is to solve for the shortcomings of first-generation digital health solutions,” said DarioHealth chief medical officer Dr. Omar Manejwala in the press release. “These platforms have made major strides, but we believe that they are missing key ingredients — including the marriage of behavioral science with AI — which is why many solutions haven’t seen a lot of meaningful and sustained engagement to date. DarioHealth’s direct-to-consumer (“D2C”) experience offers a unique opportunity to examine longitudinal consumer data through studies like this and to analyze how behaviors change over time. DarioHealth is focused on becoming a digital center of excellence that provides a complete virtual care solution to support behavior changes that improve chronic conditions through our next-generation personalization technology.”
To view the full press release, visit https://ibn.fm/DOEYA
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
